Table 1

Patient demographics and disease characteristics

 RanibizumabIntravitreal afliberceptTotal
n=101
Rq4
n=25
2q4
n=26
0.5q4
n=25
2q8
n=25
IVT-AFL
combined n=76
Sex
 Male, n (%)20 (80.0)23 (88.5)17 (68.0)19 (76.0)59 (77.6)79 (78.2)
 Female, n (%)5 (20.0)3 (11.5)8 (32.0)6 (24.0)17 (22.4)22 (21.8)
Age (years)
 Mean (SD)72.0 (6.6)70.1 (8.0)73.7 (10.1)70.6 (7.8)71.4 (8.7)71.6 (8.2)
 Range60–8656–8258–8958–8456–8956–89
 50–<65, n (%)3 (12.0)7 (26.9)6 (24.0)5 (20.0)18 (23.7)21 (20.8)
 65–<75, n (%)14 (56.0)9 (34.6)6 (24.0)13 (52.0)28 (36.8)42 (41.6)
 ≥75, n (%)8 (32.0)10 (38.5)13 (52.0)7 (28.0)30 (39.5)38 (37.6)
BCVA (ETDRS letters)
 Mean (SD)56.2 (11.7)58.8 (11.2)48.3 (13.7)54.2 (14.5)53.8 (13.7)54.4 (13.2)
 Range22–7434–7914–6820–7414–7914–79
CRT (µm)
 Mean (SD)321.2 (113.8)327.6 (97.0)354.6 (159.6)345.4 (185.9)342.4 (149.9)337.1 (141.6)
 Range175–580128–586142–761161–868128–868128–868
CNV area (mm2)
 Mean (SD)8.06 (7.49)5.07 (4.45)5.46 (3.82)6.86 (4.42)5.79 (4.26)6.35 (5.29)
 Range1.0–28.80.1–16.30.7–16.20.5–15.40.1–16.30.1–28.8
Total lesion size (mm2)
 Mean (SD)8.73 (8.19)5.47 (4.98)6.09 (4.23)7.54 (4.79)6.35 (4.70)6.94 (5.81)
 Range1.1–28.80.1–20.81.3–16.20.5–15.90.1–20.80.1–28.8
Lesion type
 Occult, n (%)10 (40.0)12 (46.2)11 (44.0)12 (48.0)35 (46.1)45 (44.6)
 Minimally classic, n (%)12 (48.0)10 (38.5)8 (32.0)7 (28.0)25 (32.9)37 (36.6)
 Predominantly classic, n (%)3 (12.0)4 (15.4)6 (24.0)6 (24.0)16 (21.1)19 (18.8)
  • BCVA, best-corrected visual acuity; CNV, choroidal neovascularisation; CRT, central retinal thickness; ETDRS, Early Treatment of Diabetic Retinopathy Study; IVT-AFL, intravitreal aflibercept.